Machina Capital S.A.S. bought a new position in CVS Health Corporation (NYSE:CVS – Free Report) during the third quarter, according to its most recent Form 13F filing with the SEC. The firm bought 9,870 shares of the pharmacy operator’s stock, valued at approximately $846,000.
Several other institutional investors and hedge funds have also made changes to their positions in the stock. Kilter Group LLC purchased a new stake in shares of CVS Health in the second quarter valued at approximately $27,000. Beaird Harris Wealth Management LLC lifted its position in CVS Health by 201.0% during the second quarter. Beaird Harris Wealth Management LLC now owns 292 shares of the pharmacy operator’s stock worth $30,000 after buying an additional 195 shares in the last quarter. J.Safra Asset Management Corp acquired a new position in CVS Health during the second quarter worth $30,000. Timbuktu Capital Management LLC acquired a new position in CVS Health during the second quarter worth $31,000. Finally, Dunhill Financial LLC purchased a new stake in CVS Health in the 2nd quarter valued at $32,000. 80.66% of the stock is currently owned by institutional investors and hedge funds.
CVS Health Price Performance
CVS stock opened at $89.37 on Monday. CVS Health Corporation has a 52-week low of $69.51 and a 52-week high of $110.68. The company has a quick ratio of 0.66, a current ratio of 0.85 and a debt-to-equity ratio of 0.71. The stock has a market cap of $114.34 billion, a price-to-earnings ratio of 10.40, a price-to-earnings-growth ratio of 0.78 and a beta of 0.58. The business has a fifty day moving average of $89.65 and a two-hundred day moving average of $89.09.
CVS Health (NYSE:CVS – Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The pharmacy operator reported $2.09 EPS for the quarter, beating the consensus estimate of $1.65 by $0.44. The business had revenue of $108.40 billion for the quarter, compared to analyst estimates of $104.72 billion. CVS Health had a return on equity of 13.65% and a net margin of 2.62%. The company’s quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.60 EPS. As a group, research analysts anticipate that CVS Health Corporation will post 8.26 earnings per share for the current year.
CVS Health Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Monday, November 2nd. Investors of record on Thursday, October 22nd were issued a $0.6650 dividend. This represents a $2.66 annualized dividend and a yield of 3.0%. The ex-dividend date was Thursday, October 22nd. CVS Health’s payout ratio is 30.97%.
Analysts Set New Price Targets
A number of brokerages have issued reports on CVS. Wells Fargo & Company cut their target price on CVS Health from $123.00 to $112.00 and set an “overweight” rating for the company in a research note on Thursday. Cantor Fitzgerald reissued a “neutral” rating on shares of CVS Health in a research report on Friday, October 9th. Robert W. Baird set a $107.00 price objective on shares of CVS Health in a report on Thursday, August 6th. Raymond James Financial set a $103.00 price objective on shares of CVS Health in a research report on Friday, November 6th. Finally, JPMorgan Chase & Co. lifted their target price on shares of CVS Health from $111.00 to $118.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 12th. Twenty-three equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $107.54.
View Our Latest Research Report on CVS Health
Recent CVS Health Headlines
Investors following CVS have been watching these headlines:
- Positive Sentiment: A separation could give the pharmacy business and CVS’s other operations sharper strategic focus and improve capital allocation. Some analysts see potential for the pieces to be worth more separately, though the plan is not expected until 2028. CVS Breakup Won’t Satisfy Washington. It Could Still Work for Wall Street.
- Positive Sentiment: CVS’s recent quarterly results were strong: earnings of $2.09 per share exceeded the $1.65 consensus estimate, while revenue also topped expectations. CVS Beat Earnings by 27% and Split in Two
- Neutral Sentiment: Wells Fargo lowered its price target to $112 from $123 but kept an Overweight rating, signaling a reduced valuation outlook while still seeing potential upside. Wells Fargo analyst rating
Insider Buying and Selling
In related news, EVP Prem Shah bought 23,855 shares of the firm’s stock in a transaction on Friday, November 6th. The shares were bought at an average price of $83.89 per share, with a total value of $2,001,195.95. Following the completion of the transaction, the executive vice president directly owned 88,516 shares of the company’s stock, valued at $7,425,607.24. This represents a 36.89% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.85% of the stock is owned by insiders.
CVS Health Company Profile
CVS Health is a U.S.-based health care company that operates retail pharmacies, provides pharmacy benefit management services, and offers health insurance and other health services. Its businesses include CVS Pharmacy, pharmacy benefit manager CVS Caremark, and Aetna, its health benefits division. The company also provides care through MinuteClinic walk-in clinics and health care businesses including Oak Street Health and Signify Health. Its services span prescription fulfillment, pharmacy benefit management, health insurance, primary care, and in-home and community-based care.
Featured Articles
- Five stocks we like better than CVS Health
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS – Free Report).
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.
